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Aromatase Inhibition Reduces Insulin Sensitivity in
Healthy Men
Fraser W. Gibb, Natalie Z.M. Homer, Abdullah M.M. Faqehi, Rita Upreti,
Dawn E. Livingstone, Kerry J. McInnes, Ruth Andrew, Brian R. Walker
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical
Research Institute, Edinburgh, EH16 4TJ, United Kingdom
Context: Deficiency of aromatase, the enzyme which catalyzes the conversion of androgens to
estrogens, is associated with insulin resistance in humans and mice.
Objective: We hypothesized that pharmacological aromatase inhibition results in peripheral in-
sulin resistance in humans.
Design: Double-blind randomized controlled crossover study.
Setting: A clinical research facility.
Participants: 17 healthy male volunteers (18 – 50 years).
Intervention: Oral anastrozole (1mg daily) and placebo, each for 6 weeks with 2 week ‘washout’
period.
Main outcome measure: Glucose disposal and rates of lipolysis were measured during a stepwise
hyperinsulinemic euglycemic clamp. Data are mean (SEM).
Results:Anastrozole therapy resulted in significant estradiol suppression (59.9 3.6 vs. 102.0 5.7
pmol/L, P  0.001) and more modest elevation of total testosterone (25.8  1.2 vs. 21.4  0.7
nmol/L, P  0.003). Glucose infusion rate, during low dose insulin infusion, was lower following
anastrozole administration (12.16 1.33 vs. 14.15 1.55 mol/kg/min, P 0.024). No differences
in hepatic glucose production or rate of lipolysis were observed.
Conclusion: Aromatase inhibition reduces insulin sensitivity, with respect to peripheral glucose
disposal, in healthy men. Local generation and action of estradiol, at the level of skeletal muscle,
is likely to be an important determinant of insulin sensitivity.
Although best known for their role in reproduction,both androgens and estrogens exert metabolic ef-
fects (1). Inmen, testosterone deficiency is associatedwith
an increased risk of type 2 diabetes mellitus (T2DM) (2)
and pharmacological androgen deprivation, employed in
the treatment of prostate cancer, is associated with dete-
riorating insulin sensitivity (3). There is inconsistent evi-
dence that testosterone replacement therapy improves in-
sulin sensitivity in hypogonadal men (4, 5).
In postmenopausal women, estrogen replacement re-
duces the risk of T2DM (6). Estrogens are generated from
substrate androgens through the action of the cytochrome
P450 enzyme aromatase (7). The circulating concentra-
tion of estrogens may be much less important than local
tissue generation, particularly in men and postmeno-
pausal women, in whom the local activity of aromatase in
skeletal muscle and adipose tissue is likely to account for
most estrogen production and action (8). It is possible that
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the metabolic phenotype in androgen-deficient men is
largely a consequence of downstream estrogen deficiency.
Supporting this hypothesis, male aromatase knock out
mice have increased adiposity (9), hepatic steatosis (10)
and insulin resistance (11), with similar features observed
in rare cases of human aromatase deficiency (12); in both
cases, estrogen replacement largely reverses the abnormal
phenotype. In healthy male volunteers anastrozole has
been shown to increase adiposity, particularly in the intra-
abdominal compartment (13). Aromatase inhibitors are
widely used for long-term treatment in breast cancer, but
any effect on fuel metabolism has not been addressed.
We hypothesized that pharmacological aromatase in-
hibition induces insulin resistance in healthy male volun-
teers. To test this hypothesis we performed a randomized
placebo-controlled crossover study using the aromatase
inhibitor anastrozole, assessing insulin sensitivity with
gold-standard stable isotope tracer methodology.
Subjects and Methods
Study design
Thiswas a double-blind, randomized placebo-controlled bal-
anced crossover study in healthy male volunteers. Ethical ap-
proval was obtained from the Lothian Research Ethics Commit-
tee and informed written consent was obtained from
participants.
Following a screening visit, participants received 6 weeks of
anastrozole (1 mg daily; Astra Zeneca) and 6 weeks of placebo,
administered in identical capsules (Tayside Pharmaceuticals), in
random order with a 2 week ‘washout’ period.
Participants
Participants were recruited through newspaper and poster
advertisements. Inclusion criteria were men aged 18 to 65 years
with normal screening blood tests (urea & electrolytes, liver
function tests, lipid profile, thyroid function tests and full blood
count). Exclusion criteriawere any significant current illness, use
of regular medication, alcohol excess (defined as greater than 28
U per week) and inability to give informed consent. All screened
volunteers (n  20) fulfilled these criteria, although three indi-
viduals elected not to proceed to randomization. Adherence was
assessed by the presence of anastrozole in plasma and suppres-
sion of circulating estrogens in the active phase.
Outcomes
The primary outcome measure was insulin sensitivity as as-
sessed by glucose disposal during a hyperinsulinemic-euglycemic
clamp (14). Additional endpoints included rates of endogenous
glucose production and lipolysis, body fat, lipid profile, plasma
adipocytokines and mRNA transcript abundance in subcutane-
ous adipose tissue.
Clinical methods
Participants attended the Clinical Research Facility at 07:30
hours following an overnight fast on two occasions (at comple-
tion of each 6 week course of tablets). Height, weight and blood
pressure (BP) (seated)weremeasured.Body fatwas assessedwith
an OMRON BF306 bioimpedance device (OMRON Health-
care). A three-phase hyperinsulinemic-euglycemic clamp study
was conducted with infusion of d2-glucose (6,6-2H2-glucose)
and d5-glycerol (1,1,2,3,3,-2H5-glycerol) tracers over 270 min-
utes. From 0 to 90 minutes only stable isotope tracers were in-
fused, with initial priming doses of d2-glucose (17mol/kg) and
d5-glycerol (1.6 mol/kg) over one minute, followed by contin-
uous infusion of d2-glucose (0.22mol/kg/min) and d5-glycerol
(0.11 mol/kg/min). Tracer infusion rates were maintained for
the remainder of the clamp study. From 90 to 180minutes, low-
dose insulin (Actrapid; Novo Nordisk; 10 mU/m2/min) was in-
fused to assess suppression of lipolysis and endogenous glucose
production. From 180 to 270 minutes, high-dose insulin was
infused (40 mU/m2/min) to assess peripheral glucose disposal.
Between90and270minutes, 20%dextrose (Baxter)was infused
to maintain euglycemia (4.5 – 5.5 mM) as determined by mea-
surement of arterialized blood samples every 5 minutes (Accu-
Chek Advantage; Roche). Arterialized venous blood samples
were obtained at baseline and as 4 steady-state samples taken
over 15 minutes at the end of each phase of the clamp study.
Biopsies of subcutaneous, peri-umbilical adipose tissue were
taken2days in advanceof clampstudies using a14-gaugeneedle,
under local anesthesia, and frozen immediately on dry ice.
Laboratory methods
Glucose, urea and electrolytes, thyroid and liver function and
lipid profile were measured by autoanalyzer (Architect c16000
analyzer; Abbott Diagnostics Ltd). SHBG was measured by en-
zyme-linked immunoassay (Demeditec Diagnostics); plasma in-
sulin by ultrasensitive ELISA (DRG); LH by in-house ELISA
(Supplemental material); plasma nonesterified fatty acids (NE-
FAs) by a coupled enzyme reaction assay (Zen-Bio Inc); and
plasma leptin, monocyte chemoattractant protein 1, interleukin
8, adiponectin and resistin by Milliplex immunoassay (Merck
Millipore). Plasma glucose, d2-glucose, glycerol and d5-glycerol
werequantifiedbygas chromatography/mass spectrometry (15).
mRNA abundance of transcripts of interest in subcutaneous ab-
dominal adipose tissue was assessed by real-time quantitative
PCR (16) and presented in relation to that of the housekeeping
gene cyclophylin A, which did not differ between groups and is
not known to be influenced by sex steroid hormones.
Plasma testosterone and androstenedione,were quantified by
LC-MS/MS (17), adapted for smaller volume of plasma (30 L)
and using Oasis HLB 10 mg cartridges (Waters, Manchester,
UK). Estradiol and estrone were quantified by LC-MS/MS (18).
Bioavailable and free testosterone were calculated as previously
described (19). Plasma anastrozole was quantified by LC-
MS/MS (Supplemental material).
Tracer kinetic calculations
Steady state of tracer:tracee ratios (TTR)was tested by Spear-
man’s correlation of time vs TTRs of the 4measurements during
each steady state period and steady state acceptedwhen P .10.
Tracer kinetics were calculated using mean values from the rel-
evant steady state period of the hyperinsulinemic-euglycemic
clamp. M value  glucose infusion rate at steady state; rate of
disposal (Rd)of glucosed2-glucose infusion rate / tracer:tracee
ratio (TTR); endogenous glucose production (EGP)  Rd glu-
cose – glucose infusion rate; and rate of appearance (Ra) of glyc-
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erol d5-glycerol infusion rate / TTR. Adjustments were made
to account for naturally occurring mass2 glucose.
Sample size and statistical analysis
Based on previously published data (20), a sample size of 20
was calculated to have 80%power to detect a 15%difference in
glucose disposal to P  .05. Due to difficulties in recruitment
only 17 participants completed the study. All statistical analyses
were performed using SPSS for Windows, version 19 (IBM).
Data are presented as mean (SEM). Comparisons between the
anastrozole and placebo treatment periods were assessed with
paired Student’s t-tests. When data were not normally distrib-
uted, logarithmic transformation was undertaken. When trans-
formation did not result in normally distributed data, Related-
Samples Wilcoxon Signed Rank Test was employed.
Results
Participant characteristics
17 individuals entered the study, all of whom com-
pleted the protocol with no significant adverse events re-
ported. The first treatment phase was anastrozole in nine
subjects and placebo in the remaining eight. Six partici-
pants consented to paired subcutaneous adipose biopsies
at the completion of each treatment
period. The mean age of volunteers
was 27.72.5 years (range 18 – 50).
Anastrozole was detected in
plasma from all participants at the
end of the active phase, ranging from
18.4 to 197.5 ng/mL (mean 59.9 
3.6 ng/mL), and not detected at the
end of the placebo phase. One indi-
vidual had very high anastrozole lev-
els, perhaps due to poor compliance
with therapy, so that without this
subject anastrozole levels ranged
from 18.4 to 93.6 and mean 50.8 
5.1 but resultswere not substantially
affected if this participant was omit-
ted from analysis., and therewere no
correlations between anastrozole
concentrations and changes in insu-
lin sensitivity.
Effects of anastrozole on insulin
sensitivity
Plasma glucose concentrations
were stable (Supplemental figure 1)
and steady state d2-glucose enrich-
ments were achieved during each
phase of the hyperinsulinemic eugly-
cemic clamp (Figure 1), although
glucose TTRs fell modestly during
low-dose insulin infusion (-0.004 0.001, P .001) and
substantially during high-dose insulin infusion (-0.012
0.001, P  .001). Predicted suppression of endogenous
glucose production, inhibition of lipolysis and stimulation
of peripheral glucose disposal by insulin were observed
(Tables 1 and 2).
Anastrozole had no effect upon endogenous glucose
production or insulin-mediated suppression of endoge-
nous glucose production (Table 1). During low dose in-
sulin infusion, a significantly lower glucose infusion rate
(M value) was required to maintain euglycemia and Rd
glucose tended to decrease following anastrozole admin-
istration (Table 1). During high dose insulin infusion, no
significant difference in M value was observed (Table 1).
Lipolysis, as determined by Ra glycerol, was not influ-
enced by anastrozole, although nonsignificant trends to-
wards higher plasma NEFA concentration and attenua-
tion of insulin-mediated suppression of NEFAs were
observed during low dose insulin infusion (Table 2).
Figure 1. Tracer:trace ratio for glucose (A) and glycerol (B) across the hyperinsulinemic clamp.
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Effects of anastrozole on BP, body composition
and lipids
Anastrozole administration was associated with a 4
mmHg increase in systolic BP compared with placebo
(138  3 vs. 134  3 mmHg, P  .05) although no sig-
nificant differencewas observed in diastolic BP (79 2 vs.
78 2mmHg,P .847).Heart ratewas correspondingly
significantly lower during anastrozole treatment (66  3
vs. 71  3 bpm, P  .05). No significant differences in
weight (82.2  3.4 vs. 81.8  3.4 kg, P  .404), BMI
(25.9 1.1 vs. 25.7 1.1 kg/m2, P .445) or percentage
body fat (16.4  1.9 vs. 16.4  1.9%, P  .957) were
observed between anastrozole and placebo treatment.
Plasma leptin was significantly lower following anastro-
zole (4249  999 vs. 5890  1349 pg/mL, P  .039)
although no difference was observed in adiponectin, re-
sistin, IL-8 or MCP-1 (Supplemental Table 2). Total cho-
lesterol was lower during the anastrozole phase (3.86 
0.13 vs. 4.12 0.14mmol/L, P .041), as a consequence
of nonsignificant trends towards lower HDL cholesterol
(7.4%, P  .08) and LDL cholesterol (6.6%, P  .12)
(Table 2). Aromatase inhibition exerted only minimal ef-
fects upon subcutaneous adipose mRNA transcript ex-
pression. Of 27 genes assessed (Supplemental Table 3),
only down regulation of estrogen receptor  (45.1%, P
.04) and perilipin 2 (8.8%, P  .045) were statistically
significant.
Table 1. Effect of anastrozole on indices of insulin
sensitivity for glucose metabolism.
Anastrozole Placebo P
During tracer
without insulin
infusion
Glucose (mM) 5.7 (0.3) 5.7 (0.2) 0.870
Insulin (mU/liter) 5.8 (0.8) 5.8 (1.0) 0.988
Endogenous glucose
production (mol/kg/
min)
7.77 (0.46) 7.50 (0.46) 0.271
During low dose
insulin infusion
Glucose (mM) 6.5 (0.4) 6.5 (0.3) 0.769
Insulin (mU/liter) 15.1 (1.2) 16.7 (1.8) 0.378
EGP (mol/kg/min) 3.79 (1.01) 3.37 (1.10) 0.562
% Suppression
endogenous glucose
production
61.2 (13.0) 65.0 (12.5) 0.723*
M Value (mol/kg/min) 12.16 (1.33) 14.15 (1.55) 0.024
Rd Glucose (mol/kg/
min)
15.04 (1.13) 16.46 (1.50) 0.044*
During high dose
insulin infusion
Glucose (mM) 5.7 (0.2) 5.8 (0.2) 0.651
Insulin (mU/liter) 48.1 (3.7) 53.6 (4.4) 0.298
M Value (mol/kg/min) 41.80 (3.66) 43.13 (4.16) 0.599
Data are mean (SEM). *Compared by Related-Samples Wilcoxon Signed
Rank Test.
Table 2. Effects of anastrozole on lipid profile and
insulin sensitivity indices for lipolysis.
Anastrozole Placebo P
Fasting
before
infusion
Total
cholesterol
(mM)
3.86 (0.13) 4.12 (0.14) 0.041
LDL-Cholesterol
(mM)
2.39 (0.14) 2.56 (0.14) 0.118
HDL-
Cholesterol
(mM)
1.01 (0.05) 1.09 (0.05) 0.080
Triglycerides
(mM)
1.02 (0.09) 1.05 (0.16) 0.770
NEFAs (M) 1011.6 (88.2) 982.4 (87.6) 0.793
During
tracer
infusion
without
insulin
infusion
Glycerol (M) 62.3 (5.1) 66.4 (4.7) 0.223
Ra Glycerol
(mol/kg/
min)
2.85 (0.36) 2.79 (0.34) 0.777
NEFAs (M) 1084.0 (71.0) 1051.4 (104.3) 0.785
During low-
dose
insulin
infusion
Glycerol (M) 35.5 (5.2) 38.1 (4.0) 0.388
Ra glycerol
(mol/kg/
min)
1.87 (0.19) 1.73 (0.17) 0.287
NEFAs (mol/
liter)
399.1 (43.3) 294.6 (35.4) 0.059
% Suppression
Glycerol from
baseline
52.8 (4.3) 57.3 (3.4) 0.426
% Suppression
Ra Glycerol
from baseline
28.0 (4.6) 32.0 (4.5) 0.302
% Suppression
NEFAs from
baseline
61.8 (0.04) 68.7 (0.04) 0.087
During high-
dose
insulin
infusion
Glycerol (M) 27.9 (5.0) 32.1 (3.9) 0.086
Ra Glycerol
(mol/kg/
min)
1.69 (0.18) 1.77 (0.20) 0.525
NEFAs (M) 173.8 (18.9) 153.7 (24.8) 0.437
Data are mean (SEM).
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Effects of anastrozole on sex steroid
concentrations
Aromatase inhibition resulted in a 20.5% increase in
plasma total testosterone (P  .003), a 41.3% decline in
estradiol (P  .001), a 43.6% (P  .001) fall in estrone,
and a compensatory 31.4% rise in luteinizing hormone
(LH) (P  .001) (Table 3). These pharmacodynamics
changes did not correlate with changes in insulin sensitiv-
ity (not shown).
None of the effects of anastrozolewere explained by an
“order effect”, since all were independent the order of
drug vs placebo administration (not shown).
Discussion
In a randomized, double-blind, placebo-controlled cross-
over study we have shown that aromatase inhibition with
anastrozole impairs insulin-stimulated peripheral glucose
disposal, without affecting hepatic glucose production or
lipolysis. An effect on the primary endpoint for the study
was achieved despite recruiting 17 of a target 20
participants.
Previous investigators assessed effects of letrozole ad-
ministered for 4 weeks in 18 healthy men (divided into
younger and older age groups) (21) and reported im-
proved insulin sensitivity, inferred from changes in fasting
glucose and insulin, but only in younger subjects. A sub-
sequent study by the same investigators assessed letrozole
effects over a1-weekperiod either aloneor in combination
with transdermal estradiol (22); hyperinsulinemic eugly-
cemic clamp studies suggested improved insulin sensitivity
in the letrozole group (although only after correction for
fat free mass), but not in the group receiving concomitant
estradiol replacement. However, it is difficult to conclude
that estradiol suppression is metabolically advantageous
in men, as supraphysiological estradiol replacement re-
sulted inLHsuppression and consequently subnormal tes-
tosterone concentrations. Furthermore, letrozole has been
associated with significant, sustained reductions in both
morning plasma cortisol (23) and ACTH-stimulated cor-
tisol (24), an effect which is not observedwith anastrozole
(25). It is not, therefore, possible to exclude an effect upon
glucocorticoid signaling as a mediator of any effect ob-
served with letrozole. No previous study of the metabolic
effects of aromatase inhibitors has employed gold-stan-
dard stable isotope tracer euglycemic hyperinsulinemic
clamp methodology. Other studies relying upon fasting
glucose and insulin measurements have failed to demon-
strate an effect of aromatase inhibition upon insulin sen-
sitivity (26, 27, 28), but this may reflect the lower sensi-
tivity of the methodology.
We found a significant effect of anastrozole to suppress
glucose disposal during low dose insulin infusion, mea-
sured both by M value (glucose infusion rate) and Rd
glucose (tracer kinetics). The 14.1% decrease in glucose
disposal we observed following a short course of aroma-
tase inhibitor therapy is likely to be of biological signifi-
cance. We did not detect a difference in M value during
high dose insulin infusion, which may have been a conse-
quence of a particularly insulin sensitive study population
in whom ED50 effects of insulin may occur at lower con-
centrations, combined with a predominant effect of anas-
trozole on ED50 rather than maximum insulin response.
Moreover, we do not report glucose tracer kinetic data
duringhighdose insulin infusionbecausewedidnot infuse
additional D2-glucose tracer in proportion to the in-
creased glucose infusion rate and, in this insulin-sensitive
group, this led to lowering of tracer:tracee ratios and po-
tentially artifactual underestimation of endogenous glu-
cose production (29). Glucose disposal data were also an-
alyzed following correction for fat free mass (the primary
site of glucose uptake), which did not materially affect the
result (not shown).
The absence of an effect upon Ra glycerol suggests that
aromatase inhibition does not influence lipolysis in either
the fasting or insulin-stimulated state, although the trend
for attenuation of insulin-stimulated plasma NEFA sup-
pression following anastrozole therapy suggests that there
could be a small effectwhich this studywas underpowered
todetect.Resultswere similarwhendatawere adjusted for
fat mass as well as body weight (not shown). A lack of
effect on lipolysis is supported by the minimal effects ob-
served upon adipose tissue mRNA transcript levels for
genes involved in the regulation of lipolysis, mirroring
Table 3. Effect of anastrozole on sex hormones in
plasma. Data are mean (SEM).
Anastrozole Placebo P
Testosterone
(nmol/liter)
25.8 (1.2) 21.4 (0.7) 0.003
Bioavailable
testosterone
(nmol/liter)
17.2 (1.0) 13.8 (0.7) 0.001
Calculated free
testosterone
(pmol/liter)
858 (51) 671 (36) 0.001
Androstenedione
(nmol/liter)
3.49 (0.10) 2.97 (0.12) 0.002
Estradiol (pmol/
liter)
59.9 (3.63) 102.0 (5.65) 0.001
Estrone (pmol/
liter)
71.1 (4.07) 126.1 (4.74) 0.001
SHBG (nmol/
liter)
19.1 (1.5) 20.4 (1.5) 0.06
LH (iU/liter) 3.5 (0.3) 2.4 (0.3) 0.001
doi: 10.1210/jc.2015-4146 press.endocrine.org/journal/jcem 5
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 30 March 2016. at 02:39 For personal use only. No other uses without permission. . All rights reserved.
earlier observations in aromatase knockout mice (30), al-
beit the number of paired biopsies we obtained was small
and these investigations of secondary endpoints risk being
underpowered. Since insulin stimulates skeletal muscle
NEFA uptake (31) and estrogen deprivation in mice re-
duces the capacity for skeletal muscle fat oxidation (32),
it is also possible that any change in NEFA suppression
reflects effects of aromatase inhibition in skeletal muscle.
No differences were observed in body composition as
determined by BMI, weight or body fat percentage be-
tween placebo and anastrozole phases. This is not unex-
pected after only 6 weeks of therapy. 16 weeks of aroma-
tase inhibition therapy in men has been shown to increase
body fat, particularly in the intra-abdominal compart-
ment, as assessed by sensitiveCTandDEXAanalysis (13).
Following anastrozole treatment, we observed a 28% re-
duction in leptin, consistentwith the findings of a previous
study investigating the effects of letrozole in healthy men
(21). Leptin is preferentially secreted by subcutaneous
rather thanomental adipocytes (33), raising thepossibility
that the observed difference in leptin may represent a shift
from subcutaneous to visceral adipose deposition. There
was no effect of anastrozole on subcutaneous adipose lep-
tin mRNA expression, suggesting lower serum leptin con-
centration is not a consequence of a direct effect upon
transcription in the subcutaneous depot. A subtle shift in
fat distributionmight indirectly contribute to theobserved
changes in insulin sensitivity.
Aromatase inhibition in postmenopausal women is as-
sociated with profound (90%) suppression of estradiol
(34). However this is not the case in men, where a com-
pensatory increase in LH (and substrate androgens) at-
tenuates the degree of estradiol suppression. While the
41.3% decline in estradiol we observed is consistent with
previous reports with letrozole (35, 21) (22), the compen-
satory rise in testosterone was several-fold lower. Letro-
zole is more abundant than anastrozole in mouse brain
tissue following systemic administration (36), providing a
potential explanation for themoremodest elevation inLH
with anastrozole (31.4% compared to 335%) (35). No-
tably, this is the first investigation of the metabolic effects
of aromatase inhibition to utilize LC MS/MS analysis of
plasmasex steroid concentrations.The superiorityofmass
spectrometric analysis has been demonstrated in the con-
text of aromatase inhibition, where immunometric meth-
ods are prone to significantly underestimate estradiol sup-
pression in postmenopausal women (34).
Accordingly, this study with anastrozole is less suscep-
tible than previous studies with letrozole to the criticism
that metabolic sequelae are attributable to testosterone
excess rather than estrogen deficiency, although we can-
not exclude an effect related to the modest (mean 4.4
nmol/L) rise in total testosterone. In men and postmeno-
pausal women, local generation and action of estradiol in
adipose tissueand skeletalmuscle is likely tobemorephys-
iologically relevant than distant action. Plasma concen-
tration of estradiol does not necessarily reflect tissue con-
centration, as evidenced by the similar breast tissue levels
observed in pre- and postmenopausal women, despite
markedly divergent plasma concentrations (37). In previ-
ous aromatase inhibitor studies in men (21) where supra-
physiological plasma testosterone concentrations were
achieved, the greater delivery of substrate androgens may
have limited thedesired effect ofminimizing local estrogen
generation and action in target tissues. It would be desir-
able to directly assess the effects of aromatase inhibition
upon target tissue sex steroid hormone concentration.
Anastrozole resulted in a significant reduction in total
cholesterol, in contrast to previous studies, which have
shown the opposite effect uponLDLcholesterol in healthy
younger men (21) or no effect in older men with mild
hypogonadism (27).These conflicting findingsmay reflect
differences in the populations studied as well as the less
pronounced elevation in plasma testosterone observed in
our study.
The rise in systolic BP and lower heart rate observed
during aromatase inhibitor treatmentwasunexpected and
contrasts with lower diastolic BP, elevated heart rate as
well as reduced baroreflex sensitivity in aromatase knock-
out mice (38). Estrogens are likely to exert hemodynamic
effects at both a central and peripheral level, potentially in
a gender-specific manner, demanding further detailed as-
sessment of the consequences of aromatase inhibition.
In summary, as hypothesized, in healthy men aroma-
tase inhibition resulted indecreased insulin sensitivity, pri-
marily manifest as reduced peripheral glucose disposal.
No significant effects upon hepatic glucose production or
lipolysis were observed. These results suggest suppression
of estrogen action in skeletal muscle is the principal mech-
anism through which aromatase inhibitors exert a delete-
rious effect on glucose metabolism. This lends support to
the hypothesis that, in male androgen deficiency, insulin
resistance is largely a consequence of reduced aromatase
substrate availability and consequent local estrogen defi-
ciency in target tissue. The metabolic consequences for
patients treated with aromatase inhibitors for breast can-
cer deserve closer investigation.
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